Kameel D. Farag
Interim CFO · Akari Therapeutics Plc
IndividualBuying only
- 2025
- Aug 19, 2026
- 7
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kameel D. Farag files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Hoyoung Huh - $1.50M in AKTX purchases and sales in the last 12 months
- Abizer Gaslightwala - $437K in AKTX purchases and sales in the last 12 months
- Raymond Prudo-Chlebosz - $406K in AKTX purchases and sales in the last 12 months
- Samir Rashmikant Patel - $344K in AKTX purchases and sales in the last 12 months
- Sandip I. Patel - $162K in AKTX purchases and sales in the last 12 months
- Robert B. Bazemore - $62K in AKTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kameel D. Farag?
Kameel D. Farag is a corporate insider, tracked as Interim CFO of Akari Therapeutics Plc (AKTX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Kameel D. Farag submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Kameel D. Farag been buying or selling stock?
Recorded transactions: 2 open-market purchases ($10K) and 0 open-market sales across all tracked filings.
